AAPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
ASCENTAGE PHARMA GROUP INTERNATIONAL
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 29, 2026
$15.36−0.01 (-0.07%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2021 to 2024
Gross margin
97.0%
Net margin
-41.3%
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +341.8% | – | – | – | |
| Gross profit | +397.1% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2021 | FY2021 | FY2024 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 1.26 | |
| Debt to equity | – | – | 6.43 | |
| Capex to revenue | – | – | 2.5% | |
| Diluted shares | – | – | 302M |
Cash use needs five years of cash flow figures
Ascentage Pharma Group International does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
2of 6 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero-CN¥405.43M
- Cash generatingOperating cash flow above zero-CN¥111.36M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-CN¥111.36M vs -CN¥405.43M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.44 → 1.26
- No dilutionShare count did not rise282M → 302M
- Gross margin improvedGross margin up on the prior year86.24% → 97.03%
- More efficientAsset turnover rose– → –